Celldex Therapeutics, Inc. Share Price Nasdaq
Stocks
US15117B1035
Biotechnology & Medical Research
| Market Cap | 304.54Cr 262.05Cr 246.75Cr 224.83Cr 420.66Cr 29TCr 422.33Cr 2.92TCr 1.13TCr 15TCr 1.14TCr 1.12TCr 47TCr | P/E 2026 * |
-9.24x | P/E 2027 * | -9.15x |
|---|---|---|---|---|---|
| Enterprise Value | 238.31Cr 205.06Cr 193.08Cr 175.93Cr 329.17Cr 23TCr 330.48Cr 2.29TCr 884.45Cr 12TCr 894.84Cr 875.39Cr 37TCr | EV / Sales 2026 * |
1,173x | EV / Sales 2027 * | 189x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Celldex Therapeutics, Inc.
| 1 day | +10.82% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.82% | +992.89% | - | - | 307.21Cr | |
| -3.24% | -6.89% | -5.65% | +11.20% | 4.8TCr | |
| +0.17% | -1.04% | +405.80% | +546.58% | 4.44TCr | |
| -0.86% | -0.53% | +36.92% | +20.35% | 4.27TCr | |
| -0.14% | -2.13% | +1.31% | +82.21% | 4TCr | |
| 0.00% | -2.61% | +13.09% | +42.33% | 3.28TCr | |
| -3.44% | +0.22% | - | - | 1.77TCr | |
| -0.78% | +0.53% | +19.14% | +116.26% | 1.65TCr | |
| -0.37% | -0.87% | +10.98% | +30.93% | 1.44TCr | |
| -0.86% | -1.41% | +71.82% | +39.36% | 1.34TCr | |
| Average | +0.13% | -0.53% | +69.18% | +111.15% | 3TCr | |
| Weighted average by Cap. | -0.91% | -1.10% | +84.31% | +131.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 20.31L 17.48L 16.46L 15L 28.06L 19Cr 28.17L 1.95Cr 75.39L 9.85Cr 76.27L 74.61L 31Cr | 1.27Cr 1.1Cr 1.03Cr 93.97L 1.76Cr 121.12Cr 1.77Cr 12Cr 4.72Cr 62Cr 4.78Cr 4.68Cr 195.48Cr |
| Net income | -32Cr -27Cr -26Cr -24Cr -44Cr -3.04TCr -44Cr -306.49Cr -118.46Cr -1.55TCr -119.85Cr -117.24Cr -4.9TCr | -36Cr -31Cr -29Cr -27Cr -50Cr -3.43TCr -50Cr -346.6Cr -133.96Cr -1.75TCr -135.53Cr -132.59Cr -5.54TCr |
| Net Debt | -66Cr -57Cr -54Cr -49Cr -91Cr -6.3TCr -92Cr -636.01Cr -245.81Cr -3.21TCr -248.7Cr -243.3Cr -10TCr | -64Cr -55Cr -52Cr -47Cr -88Cr -6.07TCr -88Cr -612.23Cr -236.62Cr -3.09TCr -239.4Cr -234.2Cr -9.79TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
